NICE - Endorsed Technology Appraisals 2009/2010

The following NICE Technology Appraisals were endorsed by DoH during 2009-10:

Technology Appraisals

Fully Endorsed

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA151 - Diabetes - Insulin Pump Therapy - HSC (SQSD) (NICE) 29/2009 

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA152 - Coronary Artery Disease - Drug Eluting Stents - HSC (SQSD) (NICE) 30/2009 

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA153 - Entecavir for the Treatment of Chronic Hepatitis B - HSC (SQSD) (NICE) 39/2009

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA154 - Telbivudine for the Treatment of Chronic Hepatitis B - HSC (SQSD) (NICE) 40/2009

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA157 - Venous Thromboembolism - Dabigatran - HSC (SQSD) (NICE) 31/2009

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA158 - Amantadine, Oseltamivir and Zanamivir for Influenza Prophylaxis - HSC (SQSD) (NICE) 41/2009

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA160 - Osteoporosis - Primary Prevention - HSC (SQSD) (NICE) 32/2009 

  • This guidance has been partially updated by TA464 - Bisphosphonates for treating osteoporosis, which was endorsed by the DoH in September 2017.

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA161 - Osteoporosis - Secondary Prevention Including Strontium Ranelate - HSC (SQSD) (NICE) 33/2009

  • This guidance has been partially updated by TA464 - Bisphosphonates for treating osteoporosis, which was endorsed by the DoH in September 2017.

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA163 - Infliximab for Acute Exacerbations of Ulcerative Colitis - HSC (SQSD) (NICE) 42/2009

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA164 - Febuxostat for the Treatment of Hyperuricaemia in People with Gout - HSC (SQSD) (NICE) 46/2009 

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA165 - Machine Perfusion Systems and Cold Static Storage of Kidneys from Deceased Donors - HSC (SQSD) (NICE) 43/2009

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA167 - Endovascular Stent Grafts for the Treatment of Abdominal Aortic Aneurysms - HSC (SQSD) (NICE) 47/2009

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA168 - Amantadine, Oseltamivir and Zanamivir for the Treatment of Influenza (review of TA58) - HSC (SQSD) (NICE) 44/2009 

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA170 - Rivaroxaban for the Prevention of Venous Thromboembolism after Total Hip or Total Knee Replacement in Adults - HSC (SQSD) (NICE) 48/2009

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA172 - Head and Neck Cancer (squamous cell carcinoma) - Cetuximab - HSC (SQSD) (NICE) 65/2009 

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA173 - Hepatitis B - Tenofovir Disoproxil Fumarate - HSC (SQSD) (NICE) 66/2009

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA174 - Leukaemia (chronic lymphocytic) Rituximab - HSC (SQSD) (NICE) 67/2009 

Back to top